Geneva, Switzerland and Boston, MA -- May 31, 2021 -- ObsEva SA (NASDAQ: 
OBSV / SIX: OBSN), a biopharmaceutical company developing and 
commercializing novel therapies to improve women's reproductive health, 
today announced that shareholders approved all Board proposals at its 
2021 Annual General Meeting held on May 28, 2021. 
 
 
 
   The approved items are as follows: 
 
 
   1. Shareholders approved the Annual Report, the Statutory Financial 
      Statements and the Consolidated Financial Statements for Fiscal Year 2020 
 
   2. Shareholders granted discharge to the Members of the Board of Directors 
      and to the Executive Committee for year 2020 
 
   3. Shareholders approved the proposed appropriation of the Financial Results 
      for year 2020 
 
   4. Shareholders approved the proposed elections to the Board of Directors 
      and election of the Chairman of the Board of Directors 
 
   5. Shareholders approved the proposed elections to the Compensation 
      Committee 
 
   6. Shareholders approved the re-election of PricewaterhouseCoopers SA as 
      ObsEva SA's Auditors and Independent Registered Public Accounting Firm 
 
   7. Shareholders approved the re-election of Perréard de Boccard SA as 
      Independent Representative 
 
   8. Shareholders approved the proposed compensation of the Board of Directors 
      and the Executive Committee 
 
   9. Shareholders approved the proposed increase of ObsEva SA's Authorized 
      Share Capital 
 
  10. Shareholders approved the proposed increase of ObsEva SA's Conditional 
      Share Capital for Financing Purposes 
 
  11. Shareholders approved the proposed increase of ObsEva SA's Conditional 
      Share Capital for Equity Plans 
 
  12. Shareholders approved the proposed change to ObsEva SA's Equity Incentive 
      Plan 
 
 
 
 
   For a detailed agenda, including items submitted to shareholders' vote 
and related proposals of the Board of Directors, please refer to the 
full invitation, which may be found in the Investors / General Meetings 
section of the company's website www.ObsEva.com 
 
   To access the general meetings section of the Company's website, please 
click h 
https://www.globenewswire.com/Tracker?data=mJnUVMr6u0ZrjHCygar5NsRnBy9yzhEeDYRenZvdCvsnsmc9wKipqCi0W2TD5hfsR1RSXSZBI6SlKUtAD9y8C33epbJzED48C4UqRpQnu9rPY-kIUn1_ihzKF2I0ZzJ0MMBcJX3vmtM7yJjlbQA-hlT2wkrwzbc-uml4SjrMBt4= 
e 
https://www.globenewswire.com/Tracker?data=DSc4c6__p4vvuleejoAjEstsQNOy10Ilfv6MU8N30P58rBzdAar6Jd1yAlw67YY6_DdQKyS3fZe2rfXn5-UkwAeRNm__iBEDGJ8ES9-5JR2me127mPUuZ6KZyYfA4X8qxBx1VqfrdlEyoxW7W4l1lFfrvh1CbmuMYvQI02lg5ls= 
re. 
https://www.globenewswire.com/Tracker?data=S8H1vY-3TBZr9EehSRoeTVM5xRMFP-zn5FeRpDLYoKm7fTVi8QkLQhD3lmjkOjpa3zomLLjDq2XiiF2zqRalZ4q2xiB7UunYII-LRiyCqf9NSC9Zn-S5_HGtexImeT0U3v8gF12g6tD5Ii9Sn6OUI_WzhzTwIv74RwKtbe3hxd7PeATlx1QcjReWByVOEi_3 
 
 
   To access the AGM 2021 section of the general meetings section directly, 
please click her 
https://www.globenewswire.com/Tracker?data=PZWkabd08lOHyZA-W6s3gVtDylrXjydx0eaPbZF1NyiltN6mtpn_plmioEEkc1-V6P1xcWP-2NitlJ08Tc3XS30d8xWZ--3h_n0aHBwBhOc= 
e 
https://www.globenewswire.com/Tracker?data=hOqh_vFZrewdn5YyaxrcjHU3EdjAUMFFzAAjmfpR-PJ1-A5qgbx7Zu9ze5PjnfsjROOtW7LHBcfbWIiwrtOyw9XWLvQ6MciToTUy105-G7I= 
. 
https://www.globenewswire.com/Tracker?data=uNULyeuqzpmRV2LAMNVF38U3eOWdxVSEZBldB7BSx1zMDwfTSLPOmidzq8iFGwGElZpIGNcPoUhSpxHAeSD7007gLhnBniCM3Kb8RBvjaJA= 
 
 
   To access the full invitation to the AGM 2021 directly, please click he 
https://www.globenewswire.com/Tracker?data=fs0CWnJoPL-VZpoJ8cWcxTOFprRkpKolhXkcrcoveAy_bafCdqopR_J88qQ-xv3MAzyOYi-jeO1xu7twIDSlST5Lo0BFETJ7zm-NRZ78UmcU1F7VT7M-03t44vf7dsxrK2PpNRKHz4_CEFvyVHqYoQ== 
r 
https://www.globenewswire.com/Tracker?data=1IrtssYXgXrtRUuz6JsneGZDU6kx4VP1V_wHp2ekP5qmHYaqISwfd0dY2I9AlxVw8Ash6SVdSmpawMWdPiZBVuV7OhydYdgWWQm5LlHB1Y2YXGO4yGPKDYIwNxo_-ylEnsJ6nY68thPZ7raeL62TKQ== 
e. 
https://www.globenewswire.com/Tracker?data=fkLz3h-ZI7PSznikzLThsdskK19YDA3qsU4joojF38NprfuHeoAi1W6YWPrQ3rjpmI0QRhB-swHEYTxm8BlQ4JLA0khN9Ytqr_hEuGlq6mHhrvm27SRY37C4uY4JKbmiueePVbg8Vv5TvxXr-sCyOkRV1SKLdNlGm6zsm2J786U= 
 
 
 
 
   About ObsEva 
 
   ObsEva is a biopharmaceutical company developing and commercializing 
novel therapies to improve women's reproductive health and pregnancy. 
Through strategic in-licensing and disciplined drug development, ObsEva 
has established a late-stage clinical pipeline with development programs 
focused on treating endometriosis, uterine fibroids and preterm labor. 
ObsEva is listed on the Nasdaq Global Select Market and is trading under 
the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is 
trading under the ticker symbol "OBSN". For more information, please 
visit www.ObsEva.com. 
 
 
 
   For further information, please contact: 
 
 
 
   CEO Office Contact: 
 
   Shauna Dillon 
 
   Shauna.dillon@obseva.ch 
https://www.globenewswire.com/Tracker?data=KDWrUq7ooYAgKPTEAsev7eqemRHL28v94au5M-2AU5F-rSxPqAgN2XbsqdeZb3uQ5eyS3848vU6LQtmvj4hO3XpQhUOGcCepKuy1AkDu0_Y= 
 
 
   +41 22 552 1550 
 
   Investor Contact: 
 
   Joyce Allaire 
 
   jallaire@lifesciadvisors.com 
https://www.globenewswire.com/Tracker?data=5-hc--BMuW--0r5CxHKLi8amNuNdlXdxxVgK0doFA2ExFRX_WNlATnCuoNXHA5zrpjxU9EFn06amRN2v9ugxGdFU4ttyuidd1Lr9Gt3qXbCEd8N0joYLtcnNEdSaFPWz 
 
 
   +1 (617)-435-6602 
 
   # 
 
 
 
 
 
   Attachment 
 
 
   -- Press Release in Pdf 
      https://ml-eu.globenewswire.com/Resource/Download/c52d2d34-67f9-40ce-8645-43edcb7b02e9

(END) Dow Jones Newswires

May 31, 2021 01:00 ET (05:00 GMT)